Meaningful tumor reduction in clinical trial patients with advanced CSCC1,2
Response in patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation1
Patient responses
These are examples from the 31% of patients who had a PR in the combined analysis of patients who received LIBTAYO 3 mg/kg Q2W in Study 1540.1
Individual patient responses may vary.
Supra- clavicular Lesion
History2
Metastatic CSCC
Supraclavicular lesion with distant metastasis
85-year-old male
Right Auricular Lesion
History2
Locally advanced CSCC
Clinical judgment was that tumor would be unlikely to respond to RT
57-year-old male
Right Cranial Lesion
Right Auricular Lesion
History2
Locally advanced CSCC
MDT deemed that radiotherapy was contraindicated
70-year-old male
Cranial lesion
Auricular lesion
Auricular lesion
These are examples from the 15% of patients who had a CR in the combined analysis of patients who received LIBTAYO 3 mg/kg Q2W in Study 1540.1
Left Auricular Lesion
History2
Locally advanced CSCC
Anterior auricular lesion that would have required an auriculectomy
The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.1
CR=complete response; CSCC=cutaneous squamous cell carcinoma; ICR=independent central review; MDT=multidisciplinary team; PR=partial response; Q2W=every 2 weeks; RECIST=Response Evaluation Criteria in Solid Tumors; RT=radiation therapy; WHO=World Health Organization.
This video reviews the clinical trial
designs, efficacy results, and safety data of LIBTAYO. It also includes a case study discussion of
a 57-year-old patient with locally advanced CSCC who was not a candidate for curative surgery or curative radiation, and was enrolled in the LIBTAYO clinical trial for advanced CSCC.
Chapter 1
Dr Chandra's and Dr Moody's introductions
Chapter 2
Overview of LIBTAYO
Chapter 3
LIBTAYO clinical trial designs for Study 1423 and Study 1540
Chapter 4
Efficacy results of LIBTAYO in advanced CSCC (time to response, objective response rate, duration of response)
Chapter 5
Safety profile of LIBTAYO in advanced CSCC
Chapter 6
Patient case study (57-year-old male with locally advanced CSCC)
References:1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron PharmaceuticaIs, Inc., and sanofi-aventis U.S. LLC. 2. Data on file. Regeneron Pharmaceuticals, Inc.